Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
avtx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Avalo Therapeutics, Inc. (AVTX) measures how much investors pay for each dollar of the company's trailing earnings. AVTX's current PE ratio of N/A is calculated by dividing its stock price of $12.74 by its TTM earnings per share of -$4.21.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Avalo Therapeutics, Inc.You AVTX | $144M | N/A | — | -$4.21 |
 Aardvark Therapeutics, Inc. Common Stock AARD | $78M | N/A | — | -$2.64 |
 Black Diamond Therapeutics, Inc. BDTX | $106M | 6.18x | — | $0.39 |
 Coherus Oncology, Inc. CHRS | $174M | N/A | — | -$1.41 |
 Caribou Biosciences, Inc. CRBU | $182M | N/A | — | -$1.59 |
 Enanta Pharmaceuticals, Inc. ENTA | $257M | N/A | — | -$3.84 |
 Eupraxia Pharmaceuticals Inc. EPRX | $201M | N/A | — | -$1.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-5.84 | — | |
2024-12-31 FY2024 | — | $-4.32 | — | |
2023-12-31 FY2023 | — | $-113.58 | — | |
2022-12-31 FY2022 | — | $-1062.65 | — | |
2021-12-31 FY2021 | — | $-2331.41 | — | |
2020-12-31 FY2020 | — | $-2489.12 | — | |
2019-12-31 FY2019 | — | $-809.74 | — | |
2018-12-31 FY2018 | — | $-3317.28 | — | |
2017-12-31 FY2017 | 4.96x | $1856.88 | — | |
2016-12-31 FY2016 | — | $-5371.95 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Avalo Therapeutics, Inc. (AVTX) measures how much investors pay for each dollar of the company's trailing earnings. AVTX's current PE ratio of N/A is calculated by dividing its stock price of $12.74 by its TTM earnings per share of -$4.21.
Frequently asked questions
AVTX pe ratio · 6 questionsAVTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $12.74 and TTM EPS of -$4.21. Data sourced from Financial Modeling Prep via AVTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Avalo Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08